ENTERA BIO IS-0000769 (F:5DT) — Stock Price
ENTERA BIO IS-0000769 (F:5DT) is currently trading at €2.42 EUR, up 6.14% today. Over the past 52 weeks, shares have ranged between €0.84 and €3.46. This page tracks ENTERA BIO IS-0000769's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see ENTERA BIO IS-0000769 cash conversion from operations.
ENTERA BIO IS-0000769 (5DT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ENTERA BIO IS-0000769's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
ENTERA BIO IS-0000769 Income Statement — Revenue, Profit & Earnings by Year
ENTERA BIO IS-0000769's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €42.00K | €181.00K | €0.00 | €134.00K | €571.00K |
| Cost of Revenue | €42.00K | €172.00K | €0.00 | €101.00K | €373.00K |
| Gross Profit | €0.00 | €9.00K | €0.00 | €33.00K | €198.00K |
| Research & Development | €6.00 Million | €4.50 Million | €4.51 Million | €5.85 Million | €6.77 Million |
| SG&A | €5.53 Million | €5.09 Million | €4.43 Million | €7.25 Million | €5.69 Million |
| Total Operating Expenses | €11.57 Million | €9.77 Million | €8.89 Million | €13.15 Million | €12.79 Million |
| Operating Income | €-11.53 Million | €-9.59 Million | €-8.89 Million | €-13.02 Million | €-12.22 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | — | — | — | — | €29.00K |
| Income Before Tax | €-11.44 Million | €-9.53 Million | €-8.86 Million | €-12.93 Million | €-12.25 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-11.44 Million | €-9.54 Million | €-8.89 Million | €-13.07 Million | €-12.19 Million |
ENTERA BIO IS-0000769 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ENTERA BIO IS-0000769's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €15.99 Million | €9.39 Million | €11.77 Million | €13.13 Million | €25.99 Million |
| Total Current Assets | €15.30 Million | €8.97 Million | €11.26 Million | €12.85 Million | €25.33 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | €0.00 | €126.00K | €0.00 | €246.00K | €183.00K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €2.89 Million | €1.31 Million | €1.38 Million | €1.37 Million | €3.42 Million |
| Total Current Liabilities | €2.20 Million | €1.18 Million | €1.09 Million | €1.34 Million | €3.16 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €13.10 Million | €8.08 Million | €10.39 Million | €11.75 Million | €22.57 Million |
| Retained Earnings | €-125.37 Million | €-113.93 Million | €-104.39 Million | €-95.50 Million | €-82.43 Million |
ENTERA BIO IS-0000769 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ENTERA BIO IS-0000769 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-7.37 Million | €-6.82 Million | €-7.31 Million | €-12.50 Million | €-9.06 Million |
| Capital Expenditures | €107.00K | €3.00K | €17.00K | €47.00K | €17.00K |
| Free Cash Flow | €-7.48 Million | €-6.82 Million | €-7.33 Million | €-12.55 Million | €-9.08 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €13.71 Million | €4.48 Million | €6.04 Million | €13.00K | €25.38 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €2.75 Million | €2.56 Million | €1.69 Million | €2.25 Million | €1.86 Million |
| Depreciation | €30.00K | €46.00K | €56.00K | €64.00K | €53.00K |
| Change in Cash | €6.20 Million | €-2.35 Million | €-1.29 Million | €-12.59 Million | €16.30 Million |
ENTERA BIO IS-0000769 Earnings History — EPS Actual vs. Analyst Estimates
Track ENTERA BIO IS-0000769's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 07, 2026 | — | — | — |
| Mar 26, 2026 | — | — | — |
| Nov 06, 2025 | — | — | — |
| May 08, 2025 | — | — | — |
| Mar 06, 2025 | — | — | — |
| Nov 12, 2024 | — | — | — |